Lysine‐specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti‐programmed death 1 therapy in liver cancer
Clinical and Translational Medicine · 2025-05 · 15 (5)
DOI: 10.1002/ctm2.70335 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 12.05.2025. Verfasst von Chen Liang und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Liver Neoplasms, Histone Demethylases, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Program of Shanghai Academic Research Leader, the Key Disease Joint Research Program of Xuhui District, the National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Immune checkpoint blockade, particularly targeting programmed death 1 (PD‐1) and programmed death ligand 1 (PD‐L1), shows promise in treating hepatocellular carcinoma (HCC). However, acquired resistance, especially in patients with ‘hot tumours’, limits sustained benefits. Lysine‐specific demethylase 1 (LSD1) plays a role in converting ‘cold tumours’ to ‘hot tumours’, but its involvement in PD‐1 inhibitor resistance in HCC is unclear.
Methods
LSD1 and PD‐L1 expression, along with CD8 + T cell infiltration, were assessed using immunohistochemistry in HCC tissues, correlating these markers with patient prognosis. The impact of LSD1 deletion on tumour cell proliferation and CD8 + T cell interactions was examined in vitro. Mouse models were used to study the combined effects of LSD1 inhibition and anti‐PD‐1 therapy on tumour growth and the tumour microenvironment (TME). The clinical relevance of LSD1, CD74 and effector CD8 + T cells was validated in advanced HCC patients treated with PD‐1 blockade.
Results
LSD1 overexpression in HCC patients correlated with reduced PD‐L1 expression, less CD8 + T cell infiltration and poorer prognosis. LSD1 deletion increased PD‐L1 expression, boosted effector CD8 + T cells in vitro and inhibited tumour growth in vivo. While anti‐PD‐1 monotherapy initially suppressed tumour growth, it led to relapse upon antibody withdrawal. In contrast, combining LSD1 inhibition with anti‐PD‐1 therapy effectively halted tumour growth and prevented relapse, likely through TME remodelling, enhanced CD8 + T cell activity and improved CD74‐mediated antigen presentation. Clinically, low LSD1 expression was associated with better response to anti‐PD‐1 therapy.
Conclusion
LSD1 deletion reshapes the TME, enhances CD8 + T cell function and prevents acquired resistance to anti‐PD‐1 therapy in HCC. The combination of LSD1 inhibitors and PD‐1 blockade offers a promising strategy for overcoming resistance in advanced HCC. Key points Uncovering the synthetic lethality resulting from LSD1 deletion and PD1 inhibitor co‐administration, evaluating their combined effects on tumour growth and TME remodelling. Elucidating the mechanism underlying the combined therapy of LSD1 deletion with PD1 inhibition for HCC. Exploring the implications of LSD1, CD74 and effector CD8 + T cell expression levels in advanced HCC patients undergoing anti‐PD1 treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China.
- Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
- Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
- Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education of the People's Republic of China, Shanghai, China.
- Department of Medical Oncology, Shanghai Geriatric Medical Center (Zhongshan Hospital, Fudan University Minhang Meilong), Shanghai, China.
- Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Chen Liang, Guo-Ming Shi, Jia-Cheng Lu
Förderung
- the Program of Shanghai Academic Research Leader
- the Key Disease Joint Research Program of Xuhui District
- the National Natural Science Foundation of China
- Shanghai Sailing Program
- the Outstanding Resident Clinical Postdoctoral Program of Zhongshan Hospital
- Fudan Undergraduate Research Opportunities Program
- the National Science and Technology Major Project of China
Zitieren
APA
Liang, C., Ye, M., Yu, L., Zhang, P. F., Guo, X. J., Meng, X. L., Zeng, H. Y., Hu, S. Y., Zhang, D. H., Sun, Q. M., Shen, Y. H., Cai, J. B., Li, S. Q., Chen, Z., Shi, Y. H., Ke, A. W., Shi, Y. G., Zhou, J., Fan, J., …, & Lu, J. C. (2025). Lysine‐specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti‐programmed death 1 therapy in liver cancer. Clinical and Translational Medicine, 15(5). https://doi.org/10.1002/ctm2.70335
Vancouver
Liang C, Ye M, Yu L, Zhang PF, Guo XJ, Meng XL, et al. Lysine‐specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti‐programmed death 1 therapy in liver cancer. Clinical and Translational Medicine. 2025;15(5). doi:10.1002/ctm2.70335
BibTeX
@article{Liang2025,
author = {Liang, Chen and Ye, Mu and Yu, Lei and Zhang, Peng-Fei and Guo, Xiao-Jun and Meng, Xian-Long and Zeng, Hai-Ying and Hu, Shu-Yang and Zhang, Dao-Han and Sun, Qi-Man and Shen, Ying-Hao and Cai, Jia-Bin and Li, Shuang-Qi and Chen, Zhen and Shi, Ying-Hong and Ke, Ai-Wu and Shi, Yujiang G and Zhou, Jian and Fan, Jia and Wu, Fei-Zhen and Huang, Xiao-Yong and Shi, Guo-Ming and Tang, Zheng and Lu, Jia-Cheng},
title = {Lysine‐specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti‐programmed death 1 therapy in liver cancer},
journal = {Clinical and Translational Medicine},
year = {2025},
volume = {15},
number = {5},
doi = {10.1002/ctm2.70335}
}
EUVIMED